Aurora Innovation, Inc.
AURAurora Innovation, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk.
The price is topping out (15 weeks in). Underneath, the last four quarters read mixed. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Aurora Innovation, Inc. trades at $7.2, losing momentum at the top and 15 weeks into that stage. That is +39.8% against its own 200-day average. It sits at 88% of a 52-week range of $4 to $8. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (1 week and counting).
Today the stock is losing momentum at the top — week 15 of stage 3. At $7.2 it trades +39.8% versus its 200-day average and sits at 88% of its 52-week range ($4–$8).
Against the market, two honest reads. Cumulative: over the last 5.2 years the stock moved −27% while the S&P 500 moved +85% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (1 week and counting; last ahead the week of 2026-07-31) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
P/E does not price Aurora Innovation, Inc. — earnings are negative, so there is no multiple to rank against its own history. The revenue and margin lines below are where a turn, when it comes, would show first. A P/E returns here the first period the bottom line turns positive.
With earnings negative, P/E does not price — there is no multiple to rank against its own history. The revenue and margin lines below are where the turn, when it comes, will show first.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read.
Aurora Innovation, Inc. reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
4-Factor Sector Score
47.6/100 — rank 26 of 29 in Auto Parts · 44% evidence confidence · provisional, ranked below fully-evidenced peers
Aurora Innovation, Inc. scores 47.6 out of 100 against the 29 companies it is compared with in Auto Parts, ranking 26. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 14 + 5 + 10 + 18.6 = 47.6. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Aurora Innovation, Inc. reported $0.0 B of revenue in the Mar 26 quarter. The last full year, FY25, came in at $0.0 B. The last four reported quarters add to $0.0 B. A multi-year compound rate is not shown because the annual history behind it is too short to compute one honestly.
FY25 revenue came in at $0.0 B (−100.0% on the year). The latest quarter (Mar 26) printed $0.0 B, null year on year.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
A clean operating margin is not in our numbers for Aurora Innovation, Inc. — its accounts do not report the operating-profit line this section reads, which is common for lenders and holding companies. The sections above and below carry the readings this company's filings do support.
This company's accounts do not report the operating-profit line this section reads — common for lenders and holding companies classified outside the financial bucket. The revenue and net-profit sections are the cleaner reads for Aurora Innovation, Inc..
Why: the numbers show the operating margin move clearly, but the cost lines behind it sit below what we hold — so we state the move without inventing its driver.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Aurora Innovation, Inc. posted a net loss of $0.2 B in the Mar 26 quarter. The full FY25 year was a loss of $0.8 B. The same quarter a year earlier lost $0.3 B. 10 of the last 10 reported quarters were loss-making.
Mar 26 profit was $−0.2 B, null year on year. On the full year, FY25 printed $−0.8 B (null).
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Aurora Innovation, Inc.'s cash-flow history is too thin to judge how much reported profit converts into cash. In FY25 that was $−0.6 B of operating cash against $−0.8 B of profit. After $0.0 B of capital spending, $−0.6 B was left as free cash. Cash resolution here is annual, because quarterly cash statements are not published.
FY25: operating cash of $−0.6 B against reported profit of $−0.8 B, leaving free cash of $−0.6 B after $0.0 B of capital spending.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Aurora Innovation, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Nothing is estimated in place of the missing day-counts, so no cash-cycle chart is drawn.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Aurora Innovation, Inc. earns a ROE of −38% in FY25. That is up from a trough of −97% in FY22. Return on invested capital clears the cost of that capital by −47.9 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is −2,457.1% net margin on 0.04× asset turns.
FY25 ROE is −38%, recovered from a FY22 trough of −97% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY22): −2,457.1% net margin × 0.04× asset turns × 1.12× balance-sheet leverage ≈ −110.1% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: −29.3% − 18.6% = a −47.9 pp spread. The 18.6% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Dividend
Aurora Innovation, Inc. pays no dividend. Across the last 10 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
Aurora Innovation, Inc. does not currently pay a dividend. Across the last 10 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Aurora Innovation, Inc. carries total debt of $0.1 B against shareholder equity of $1.9 B as of Jun 26, a debt-to-equity of 0.04 — effectively unlevered. On the annual view that ratio went from 0.04 in FY21 to 0.04 in FY25. The returns elsewhere on this page are therefore earned rather than borrowed.
Jun 26: total debt of $0.1 B against shareholder equity of $1.9 B — a debt-to-equity of 0.04. On the annual view, debt-to-equity went from 0.04 (FY21) to 0.04 (FY25). The returns on this page are earned, not borrowed.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
12.8% of Aurora Innovation, Inc.'s tradable float is currently sold short — a large bloc is positioned against it. At typical trading volumes those positions would take about 6.8 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 12.8% of the float is sold short, and at typical trading volumes it would take about 6.8 days to buy those positions back. A large bloc is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Aurora Innovation, Inc.: the Z-score reads 23.53. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 23.53 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 23.53.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Garrett Motion Inc.GTX | 64.4/100Thin evidence · provisional56% evidence | FADING | 21.7/35 Revenue — · PAT — · OPM change 1 pp 39% evidence | 18.3/25 ROCE 14.2% · OPM 13.9% 76% evidence | 10.1/20 P/E 19.9× · PEG — 15% evidence | 14.3/20 RS sector 39.8% · RS bench 35.8% · 1Y 148.3%11 of 12 weeks ahead 100% evidence |
| Exact sum: 21.7 + 18.3 + 10.1 + 14.3 = 64.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 2Douglas Dynamics, Inc.PLOW | 58.4/100Thin evidence · provisional55% evidence | ASLEEP | 21.8/35 Revenue 15.5% · PAT -17.2% · OPM change 4.4 pp 40% evidence | 9.3/25 ROCE 1.9% · OPM 7.2% 57% evidence | 13.0/20 P/E 19× · PEG 1.04 65% evidence | 14.3/20 RS sector 6.2% · RS bench 3% · 1Y 44.4%3 of 12 weeks ahead 70% evidence |
| Exact sum: 21.8 + 9.3 + 13 + 14.3 = 58.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 3Allison Transmission Holdings, Inc.ALSN | 57.4/100Mixed-positive evidence66% evidence | ASLEEP | 13.8/35 Revenue 14% · PAT -28% · OPM change -18.6 pp 53% evidence | 13.7/25 ROCE 3.2% · OPM 13.9% 57% evidence | 14.8/20 P/E 18.2× · PEG 0.71 65% evidence | 15.1/20 RS sector 7.7% · RS bench 4.4% · 1Y 39.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 13.8 + 13.7 + 14.8 + 15.1 = 57.4 · Decision use: Price leads the evidence: RS versus the benchmark is 4.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 4BorgWarner Inc.BWA | 57.2/100Mixed-positive evidence66% evidence | FADING | 20.7/35 Revenue 2.3% · PAT 20.1% · OPM change 2.8 pp 53% evidence | 12.1/25 ROCE 3.2% · OPM 9.5% 57% evidence | 10.9/20 P/E 32.1× · PEG 1.19 65% evidence | 13.5/20 RS sector 10.8% · RS bench 7.4% · 1Y 63.6%10 of 12 weeks ahead 100% evidence |
| Exact sum: 20.7 + 12.1 + 10.9 + 13.5 = 57.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Magna International Inc.MGA | 56.8/100Thin evidence · provisional56% evidence | TURNING | 19.5/35 Revenue — · PAT — · OPM change 1.2 pp 39% evidence | 10.2/25 ROCE 3.1% · OPM 4.3% 76% evidence | 9.5/20 P/E 24.1× · PEG — 15% evidence | 17.6/20 RS sector 16.4% · RS bench 12.9% · 1Y 64.9%5 of 12 weeks ahead 100% evidence |
| Exact sum: 19.5 + 10.2 + 9.5 + 17.6 = 56.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 6Atmus Filtration Technologies Inc.ATMU | 53.0/100Mixed-positive evidence66% evidence | ASLEEP | 19.2/35 Revenue 10% · PAT 14.1% · OPM change 1 pp 53% evidence | 14.9/25 ROCE 5.8% · OPM 14.4% 57% evidence | 10.4/20 P/E 22.3× · PEG 1.45 65% evidence | 8.5/20 RS sector -2.5% · RS bench -5.5% · 1Y 34.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.2 + 14.9 + 10.4 + 8.5 = 53 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7O'Reilly Automotive, Inc.ORLY | 53.0/100Thin evidence · provisional56% evidence | BASING | 18.5/35 Revenue — · PAT — · OPM change 0.6 pp 39% evidence | 18.5/25 ROCE 13.2% · OPM 18.5% 76% evidence | 9.2/20 P/E 29.3× · PEG — 15% evidence | 6.8/20 RS sector -10.9% · RS bench -13.5% · 1Y -11.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.5 + 18.5 + 9.2 + 6.8 = 53 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8Gentex CorporationGNTX | 52.9/100Thin evidence · provisional56% evidence | ASLEEP | 18.3/35 Revenue — · PAT — · OPM change -1.3 pp 39% evidence | 15.9/25 ROCE 5.6% · OPM 18.3% 76% evidence | 10.9/20 P/E 13.4× · PEG — 15% evidence | 7.8/20 RS sector -8.2% · RS bench -11% · 1Y -9.4%2 of 12 weeks ahead 100% evidence |
| Exact sum: 18.3 + 15.9 + 10.9 + 7.8 = 52.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Advance Auto Parts, Inc.AAP | 51.4/100Thin evidence · provisional56% evidence | TURNING | 22.5/35 Revenue — · PAT — · OPM change 7.7 pp 39% evidence | 6.4/25 ROCE 1% · OPM 2.6% 76% evidence | 8.7/20 P/E 80.8× · PEG — 15% evidence | 13.8/20 RS sector 1.4% · RS bench -1.7% · 1Y -0.4%4 of 12 weeks ahead 100% evidence |
| Exact sum: 22.5 + 6.4 + 8.7 + 13.8 = 51.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10PHINIA Inc.PHIN | 51.2/100Thin evidence · provisional56% evidence | ASLEEP | 17.9/35 Revenue — · PAT — · OPM change 0.1 pp 39% evidence | 10.3/25 ROCE 2.8% · OPM 7.9% 76% evidence | 9.7/20 P/E 23.6× · PEG — 15% evidence | 13.3/20 RS sector 10.8% · RS bench 7.4% · 1Y 53.6%4 of 12 weeks ahead 100% evidence |
| Exact sum: 17.9 + 10.3 + 9.7 + 13.3 = 51.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11XPEL, Inc.XPEL | 50.7/100Thin evidence · provisional60% evidence | TURNING | 19.8/35 Revenue 12.4% · PAT 12.5% · OPM change 0.4 pp 53% evidence | 14.0/25 ROCE 4.6% · OPM 11.1% 57% evidence | 8.1/20 P/E 23.2× · PEG 1.98 65% evidence | 8.8/20 RS sector -2.6% · RS bench -5.6% · 1Y 36.7%2 of 12 weeks ahead 70% evidence |
| Exact sum: 19.8 + 14 + 8.1 + 8.8 = 50.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Genuine Parts CompanyGPC | 49.3/100Thin evidence · provisional56% evidence | BREAKING OUT | 17.3/35 Revenue — · PAT — · OPM change -0.3 pp 39% evidence | 10.4/25 ROCE 3% · OPM 4.6% 76% evidence | 8.5/20 P/E 471.9× · PEG — 15% evidence | 13.1/20 RS sector -0.7% · RS bench -3.7% · 1Y -0.4%6 of 12 weeks ahead 100% evidence |
| Exact sum: 17.3 + 10.4 + 8.5 + 13.1 = 49.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13Dorman Products, Inc.DORM | 49.1/100Mixed-negative evidence66% evidence | BREAKING OUT | 13.3/35 Revenue 5% · PAT -11.2% · OPM change -4.7 pp 53% evidence | 12.5/25 ROCE 3% · OPM 11.1% 57% evidence | 7.5/20 P/E 16.9× · PEG 2.33 65% evidence | 15.8/20 RS sector 4.1% · RS bench 1% · 1Y 5.9%10 of 12 weeks ahead 100% evidence |
| Exact sum: 13.3 + 12.5 + 7.5 + 15.8 = 49.1 · Decision use: Price leads the evidence: RS versus the benchmark is 1%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 14Autoliv, Inc.ALV | 48.5/100Thin evidence · provisional56% evidence | ASLEEP | 14.9/35 Revenue — · PAT — · OPM change -1.3 pp 39% evidence | 13.7/25 ROCE 4.3% · OPM 8.6% 76% evidence | 10.8/20 P/E 13.6× · PEG — 15% evidence | 9.1/20 RS sector -3.7% · RS bench -6.5% · 1Y 10.8%2 of 12 weeks ahead 100% evidence |
| Exact sum: 14.9 + 13.7 + 10.8 + 9.1 = 48.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15Gentherm IncorporatedTHRM | 47.5/100Thin evidence · provisional56% evidence | BREAKING OUT | 13.3/35 Revenue — · PAT — · OPM change -1.9 pp 39% evidence | 6.2/25 ROCE 1% · OPM 2.9% 76% evidence | 9.0/20 P/E 39.2× · PEG — 15% evidence | 19.0/20 RS sector 15.3% · RS bench 12% · 1Y 31.5%10 of 12 weeks ahead 100% evidence |
| Exact sum: 13.3 + 6.2 + 9 + 19 = 47.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 16Lear CorporationLEA | 45.6/100Thin evidence · provisional56% evidence | ASLEEP | 19.1/35 Revenue — · PAT — · OPM change 0.3 pp 39% evidence | 9.7/25 ROCE 2.9% · OPM 4.4% 76% evidence | 11.3/20 P/E 12.2× · PEG — 15% evidence | 5.5/20 RS sector -3.5% · RS bench -6.4% · 1Y 31.3%5 of 12 weeks ahead 100% evidence |
| Exact sum: 19.1 + 9.7 + 11.3 + 5.5 = 45.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Modine Manufacturing CompanyMOD | 42.3/100Thin evidence · provisional56% evidence | ASLEEP | 15.7/35 Revenue — · PAT — · OPM change -0.6 pp 39% evidence | 12.6/25 ROCE 4% · OPM 10.9% 76% evidence | 8.6/20 P/E 100.4× · PEG — 15% evidence | 5.4/20 RS sector -2.9% · RS bench -5.9% · 1Y 48.1%5 of 12 weeks ahead 100% evidence |
| Exact sum: 15.7 + 12.6 + 8.6 + 5.4 = 42.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 18AutoZone, Inc.AZO | 41.8/100Mixed-negative evidence81% evidence | BASING | 15.6/35 Revenue 5.8% · PAT -3.3% · OPM change -0.3 pp 83% evidence | 17.0/25 ROCE 9.2% · OPM 19.1% 76% evidence | 5.8/20 P/E 24× · PEG 2.4 65% evidence | 3.4/20 RS sector -22.3% · RS bench -24.6% · 1Y -25%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.6 + 17 + 5.8 + 3.4 = 41.8 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 19Visteon CorporationVC | 41.5/100Thin evidence · provisional56% evidence | ASLEEP | 14.1/35 Revenue — · PAT — · OPM change -5.4 pp 39% evidence | 11.4/25 ROCE 3.1% · OPM 4.3% 76% evidence | 11.1/20 P/E 13× · PEG — 15% evidence | 4.9/20 RS sector -8.1% · RS bench -10.8% · 1Y -7.7%5 of 12 weeks ahead 100% evidence |
| Exact sum: 14.1 + 11.4 + 11.1 + 4.9 = 41.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Dana IncorporatedDAN | 41.3/100Thin evidence · provisional51% evidence | ASLEEP | 18.1/35 Revenue 1.2% · PAT — · OPM change 2.7 pp 40% evidence | 7.8/25 ROCE 1.3% · OPM 3.2% 57% evidence | 11.5/20 P/E 3.1× · PEG — 15% evidence | 3.9/20 RS sector -5.9% · RS bench -8.9% · 1Y 57.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.1 + 7.8 + 11.5 + 3.9 = 41.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21Aptiv PLCAPTV | 40.7/100Mixed-negative evidence61% evidence | ASLEEP | 15.5/35 Revenue 5.2% · PAT -75.7% · OPM change -1.9 pp 40% evidence | 9.8/25 ROCE 2% · OPM 7.4% 57% evidence | 13.9/20 P/E 41.1× · PEG 0.67 65% evidence | 1.5/20 RS sector -39% · RS bench -40.9% · 1Y -28.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.5 + 9.8 + 13.9 + 1.5 = 40.7 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 22LKQ CorporationLKQ | 40.4/100Thin evidence · provisional56% evidence | BASING | 16.1/35 Revenue — · PAT — · OPM change -1.7 pp 39% evidence | 9.7/25 ROCE 1.8% · OPM 6.3% 76% evidence | 10.7/20 P/E 14.6× · PEG — 15% evidence | 3.9/20 RS sector -24% · RS bench -26.3% · 1Y -16.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.1 + 9.7 + 10.7 + 3.9 = 40.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23The Goodyear Tire & Rubber CompanyGT | 35.4/100Thin evidence · provisional56% evidence | TURNING | 10.7/35 Revenue -3.7% · PAT -1025.6% · OPM change -1.9 pp 53% evidence | 6.0/25 ROCE -0.7% · OPM -2.3% 57% evidence | 11.4/20 P/E 7.5× · PEG — 15% evidence | 7.3/20 RS sector -13.3% · RS bench -16% · 1Y -14%1 of 12 weeks ahead 100% evidence |
| Exact sum: 10.7 + 6 + 11.4 + 7.3 = 35.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 24Mobileye Global Inc.MBLY | 34.7/100Thin evidence · provisional53% evidence | ASLEEP | 14.5/35 Revenue — · PAT — · OPM change -671.5 pp 39% evidence | 4.2/25 ROCE -0.3% · OPM -698.2% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 6.0/20 RS sector -24.4% · RS bench -26.6% · 1Y -36.5%6 of 12 weeks ahead 100% evidence |
| Exact sum: 14.5 + 4.2 + 10 + 6 = 34.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25Versigent PLCVGNT | 53.4/100Thin evidence · provisional21% evidence | FADING | 18.0/35 Revenue — · PAT — · OPM change -0.8 pp 10% evidence | 14.4/25 ROCE 10.6% · OPM 6.2% 57% evidence | 11.0/20 P/E 13.1× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —5 of 6 weeks ahead 0% evidence |
| Exact sum: 18 + 14.4 + 11 + 10 = 53.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26Aurora Innovation, Inc.this pageAUR | 47.6/100Thin evidence · provisional44% evidence | ASLEEP | 14.0/35 Revenue — · PAT — · OPM change -14731.4 pp 26% evidence | 5.0/25 ROCE -12.7% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 18.6/20 RS sector 27.1% · RS bench 23.3% · 1Y 17.4%10 of 12 weeks ahead 100% evidence |
| Exact sum: 14 + 5 + 10 + 18.6 = 47.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27Adient plcADNT | 44.1/100Thin evidence · provisional45% evidence | BASING | 20.4/35 Revenue 3.8% · PAT — · OPM change 9.3 pp 40% evidence | 8.7/25 ROCE 2.5% · OPM 3.3% 57% evidence | 9.3/20 P/E 28.5× · PEG — 15% evidence | 5.7/20 RS sector -10.1% · RS bench -13% · 1Y -3.8%0 of 12 weeks ahead 70% evidence |
| Exact sum: 20.4 + 8.7 + 9.3 + 5.7 = 44.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 28Dauch CorporationDCH | 34.8/100Thin evidence · provisional50% evidence | BASING | 12.9/35 Revenue 14.8% · PAT -704.8% · OPM change -4.4 pp 53% evidence | 6.6/25 ROCE -0.5% · OPM -1.4% 57% evidence | 10.3/20 P/E 18.2× · PEG — 15% evidence | 5.0/20 RS sector -11.3% · RS bench -14.1% · 1Y 13.4%1 of 12 weeks ahead 70% evidence |
| Exact sum: 12.9 + 6.6 + 10.3 + 5 = 34.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29QuantumScape CorporationQS | 33.1/100Thin evidence · provisional47% evidence | ASLEEP | 17.4/35 Revenue — · PAT — · OPM change — 33% evidence | 5.2/25 ROCE -9.5% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 0.5/20 RS sector -44.9% · RS bench -46.3% · 1Y -35%3 of 12 weeks ahead 100% evidence |
| Exact sum: 17.4 + 5.2 + 10 + 0.5 = 33.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Aurora Innovation, Inc.'s stock price today?
Aurora Innovation, Inc. trades at $7.2, +28.0% over the past year. The company is valued at $14.0 B. The stock sits at 88% of its 52-week range of $4–$8, +39.8% versus its 200-day average. On the tape, the price is topping out, 15 weeks in. — as of 5 August 2026.
What were Aurora Innovation, Inc.'s latest quarterly results?
Aurora Innovation, Inc. reported revenue of $0.0 B and a net loss of $0.2 B for the Mar 26 quarter. Earnings per share were $−0.11. — as of 5 August 2026.
What is Aurora Innovation, Inc.'s revenue?
Aurora Innovation, Inc. reported revenue of $0.0 B in the Mar 26 quarter. For the full FY25 fiscal year, revenue was $0.0 B (−100.0%). — as of 5 August 2026.
What is Aurora Innovation, Inc.'s profit?
Aurora Innovation, Inc. earned $−0.2 B of net profit in the Mar 26 quarter. Full-year FY25 profit was $−0.8 B. — as of 5 August 2026.
What is Aurora Innovation, Inc.'s market cap?
Aurora Innovation, Inc.'s market capitalisation is $14.0 B at a stock price of $7.2. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 5 August 2026.
Does Aurora Innovation, Inc. pay a dividend?
No — Aurora Innovation, Inc. has declared no dividend per share in any of its last 10 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 5 August 2026.
How is Aurora Innovation, Inc. performing?
Aurora Innovation, Inc. is topping out, 15 weeks in. Against the S&P 500 it has been behind on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 5 August 2026.
Is Aurora Innovation, Inc. in an uptrend?
It is stalling — the price is topping out (week 15 of stage 3), trading +39.8% versus its 200-day average and at 88% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 5 August 2026.
Is Aurora Innovation, Inc. beating the market?
Not lately — on a trailing-13-week view Aurora Innovation, Inc. is currently behind the S&P 500 (1 week and counting; last ahead the week of 2026-07-31), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 5.2 years the stock moved −27% against the S&P 500's +85% — behind the index over the full window. — as of 5 August 2026.
Will Aurora Innovation, Inc.'s stock price go up?
This page publishes no price forecast for Aurora Innovation, Inc. What it measures instead: the stock price is $7.2, the price is topping out 15 weeks in. Direction is not something this site claims to know. — as of 5 August 2026.
Is the market betting against Aurora Innovation, Inc.?
Yes — short interest is 12.8% of Aurora Innovation, Inc.'s tradable float, about 6.8 days to cover at typical volumes. A crowded short: a large bloc is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 5 August 2026.
Does Aurora Innovation, Inc. have too much debt?
No — Aurora Innovation, Inc.'s debt-to-equity is 0.04. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. The returns on this page are earned, not borrowed — as of 5 August 2026.
What is Aurora Innovation, Inc.'s capex?
Aurora Innovation, Inc. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 5 August 2026.
What is Aurora Innovation, Inc.'s cash flow?
Aurora Innovation, Inc. generated $−0.6 B of operating cash flow in FY25 and $−0.6 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $−0.8 B, so operating cash ran ahead of profit. — as of 5 August 2026.
How financially safe is Aurora Innovation, Inc.?
On the balance sheet, the Z-score reads 23.53 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 5 August 2026.
Where is Aurora Innovation, Inc. in its business cycle?
Aurora Innovation, Inc.'s FY22 operating margin was −2,642.9%, against a 2-year band of −2,642.9%–−912.5%: the low end of its own band, which is where recoveries start when they come. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 5 August 2026.
What could break the Aurora Innovation, Inc. story?
Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 5 August 2026.
Is Aurora Innovation, Inc. a stock worth studying right now?
This is not investment advice. The machine read: Aurora Innovation, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 5 August 2026.